Navigation Links
Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
Date:10/19/2009

dies suggest that ARIKACE has the potential to improve upon the standard of care in the treatment of chronic Pseudomonas lung infections, and further studies are merited in an effort to bring this medicine to market."

In the U.S., ARIKACE was administered once daily for 28 days at 70 mg, 140 mg and 560 mg doses using a novel inhalation device, the eFlow® Electronic Nebulizer (PARI Pharma GmbH). This study included member institutions of the Cystic Fibrosis Foundation's Therapeutics Development Network. In Europe, ARIKACE was administered once daily for 28 days at 280 mg and 560 mg dosages, also using the eFlow® Electronic Nebulizer. Improved lung function was dose-related with the higher 560 mg dose resulting in the greatest improvement in lung function which was sustained for 28 days after treatment ended. Adverse events reported were consistent with those expected in a population of CF patients receiving inhaled medicine, and no differences between groups in the overall rates of adverse events.

"Once-a-day ARIKACE, providing sustained improvement even after therapy ends, suggests that it is possible to treat these stubborn Pseudomonas lung infections while reducing the treatment burden that these patients currently endure," said Dr. Clancy. "Further, the potential for ARIKACE to penetrate the biofilm and achieve a sustained improvement in lung function would be an important advance in this field."

Study results have consistently demonstrated significant reduction in Pseudomonas bacterial density in both mucoid and non-mucoid strains of Pseudomonas. Mucoid strains of Pseudomonas are associated with the presence of biofilms. A biofilm is a protective gel-like barrier formed by colonies of the common and often chronic Pseudomonas bacteria. The bacterial cells encased within the biofilm are difficult to kill because many antibiotics either stick to the surface of the bi
'/>"/>

SOURCE Transave, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
2. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
3. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
4. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
5. BMEYE B.V. Completes EUR 6 Million Series B Financing Round
6. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
7. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
8. Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
9. PDL BioPharma Completes October 1 Special Dividend Payment
10. SyntheMed Completes $1.0 Million Equity Placement
11. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Japan Pharma Outlook 2015: Year to Watch out ... report to their offering. The ... from April -2014 (Annexure 1) is a game ... whether generic or innovator. The most of the companies ...
(Date:3/5/2015)... , March 5, 2015 Mallinckrodt ... global specialty biopharmaceutical company, and Ikaria, Inc. a privately-held ... into a definitive agreement under which a subsidiary of ... Dearborn -led investor group in a transaction valued at ... closing conditions, the parties expect the transaction to be ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... of the "Global Rising Stars Outlook 2015" ... for treating diseases are being sought after with fresh ... discovered. One field which is poised to bring a ... the next decades is the Stem cell therapy/Regenerative Medicine ...
Breaking Medicine Technology:Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 2Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 3Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 4Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 5Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 6Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 7Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 8Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition 9Global Pharma Rising Stars Outlook 2015 2
(Date:3/5/2015)... AxoGen, Inc. (NASDAQ: AXGN) , a ... repair market, reported record revenue of $4.79 million for ... $2.98 million in the year-ago fourth quarter demonstrating the ... “Our strong fourth quarter revenue growth reflects the market’s ... is driving increased surgeon adoption of our unique product ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
(Date:3/5/2015)... 05, 2015 TCS Healthcare Technologies (TCS), ... the population health management arena, is pleased to announce ... software, ACUITY Advanced Care™ (ACUITY) version 7.20. The session ... and the advantages of automation. , The webinar, scheduled ... be led by Jeff Frater, RN, BSN, Director of ...
(Date:3/5/2015)... 2015 University of Western States ... 1904, has launched a new center of excellence ... The Northwest Center for Lifestyle and Functional Medicine ... outreach, and conduct research in the areas of ... nutrition. The center will target efforts on the ...
(Date:3/5/2015)... 05, 2015 INTEGRATED Healthcare Strategies, ... to participate in its 2015 Children’s Hospitals Executive ... and director-level positions, and the survey results are ... report featured data on 60 executive and director ... organizations and 7 subsidiary children’s hospitals. Additionally, it ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 2Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 3Health News:AxoGen, Inc. Reports 61% Revenue Growth for the 2014 Fourth Quarter 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 2Health News:Complimentary Webinar to Explore Enhanced Version of Premier Case Management Software 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2
... a recent study researchers now say that the antidepressant ... // of being admitted to a hospital for ... 2000 on over 64,000 new antidepressant users. They evaluated ... risk for abnormal bleeding. Researchers classified serotonin reuptake ...
... who are considered obese are significantly more likely to ... recent study . They say that their finding is ... even when people are receiving treatments aimed at bringing ... have found the link between obesity and atrial fibrillation, ...
... During the rainy season as as water stagnation and ... more prevalent.//Experts attending the workshop on 'water microbiology' stressed ... their purity, as water supplies were contaminated with sewage ... ,The workshop was inaugurated by Dr C V Raghuveer, ...
... Osteoarthritis of the knee is very common, affecting almost ... an incurable illness //, so treatment is aimed at ... was studied. Acupuncture in addition to drug treatment for ... treatment alone, shows new research out of Spain. ...
... reduce cancer risk in men, but not in women, ... ,Researchers conducted a study on 13,017 French adults. The ... capsule containing 120 milligrams of ascorbic acid (vitamin C), ... carotene, 100 micrograms of selenium, and 20 milligrams of ...
... to medication show an improved clinical recovery // compared ... new study. ,Researchers examined 126 patients who suffered ... middle cerebral artery. All the patients were treated with ... onset. 63 patients were randomly assigned to receive continuous ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: